Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Replagal dosing regimens in Fabry disease
NCT00864851Phase 3Completed
- Sponsor
- Takeda
- Start
- Dec 2008
- Primary completion
- Jun 2012
- Modality
- Replacement Enzymes
- Countries
- 8
01
Overview
A Phase 3 trial of agalsidase alfa in Fabry disease (FD), sponsored by Takeda. Started Dec 2008; status: completed.
02
Drugs
agalsidase alfa
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT00864851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00864851.